Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 91Stomach Neoplasms 44Pancreatic Neoplasms 37Rectal Neoplasms 29Colonic Neoplasms 23Neoplasms 22Esophageal Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Neoplasm Metastasis 18Cholangiocarcinoma 16Adenocarcinoma Of Esophagus 16Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 12Head and Neck Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Non-Small-Cell Lung 12Adenocarcinoma 12Urinary Bladder Neoplasms 11Ovarian Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Hepatocellular 7Endometrial Neoplasms 6Breast Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Peritoneal Neoplasms 4Lung Neoplasms 4Carcinoma 4Appendiceal Neoplasms 4

Interventions

trastuzumab deruxtecan 2Trastuzumab 2Oxaliplatin 2Fluorouracil 2Cisplatin 2Capecitabine 2pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
HER2-positive Gastric Cancer × Fluorouracil × 1 year × Clear all
NCT06764875 2026-05-12

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

AstraZeneca

Phase 3 Recruiting
840 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡